Expanded Access of Sotorasib

The primary objective of this study is to provide expanded access to and characterize the safety profile of Sotorasib in participants with previously treated locally advanced/unresectable/metastatic non small-cell lung cancer (NSCLC) with KRAS p.G12C mutation in a real-world setting.

Inclusion Criteria * Age ≥ 18 years * Ineligibility for participation in any Amgen-sponsored ongoing clinical study of the investigational product * Pathologically documented, locally-advanced and unresectable or metastatic Non Small-Cell Lung Cancer (NSCLC) with KRAS p.G12C mutation confirmed through molecular testing * Exhausted other standard of care options for locally advanced and unresectable or metastatic NSCLC disease including platinum-based combination chemotherapy and programmed cell death protein 1/programmed death-ligand 1 (PD 1/PD-L1) immunotherapy (unless medically contraindicated) * Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2 Exclusion Criteria * Mixed small-cell lung cancer or mixed NSCLC histology * Active brain metastases * Active hepatitis B or hepatitis C virus * Current active malignancy other than NSCLC * Currently or previously enrolled in a prior sotorasib study unless radiographic disease progression confirmed, able to remain on long term follow up of their original protocol and receives medical monitor approval * Female participants planning to become pregnant while on study through 7 days after the last dose of sotorasib